MEDI-524 (motavizumab) for the prevention of respiratory sycytial virus (RSV) disease among Native American Indian infants in the southwestern United States

Trial Identifier: MI-CP117
Sponsor: MedImmune, LLC
NCTID:: NCT00121108
Start Date: November 2004
Primary Completion Date: December 2010
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States of America, AZ Chinle, AZ, United States of America
United States of America, AZ Cibecue, AZ, United States of America
United States of America, AZ Ft. Definace, AZ, United States of America
United States of America, AZ San Carlos, AZ, United States of America
United States of America, AZ Tuba City, AZ, United States of America
United States of America, AZ Whiteriver, AZ, United States of America
United States of America, AZ Winslow, AZ, United States of America
United States of America, MD Baltimore, MD, United States of America, 21205
United States of America, NM Bloomfield, NM, United States of America
United States of America, NM Crownpoint, NM, United States of America
United States of America, NM Gallup, NM, United States of America
United States of America, NM Shiprock, NM, United States of America